Commit To Buy Syndax Pharmaceuticals At $13, Earn 21.5% Using Options

The piece evaluates selling a January 2028 put on Syndax Pharmaceuticals (SNDX) with a $13 strike, noting the current stock price of $21.36 and a trailing-12-month volatility of 68%. The put premium equates to a 10.4% annualized return, but the seller only obtains shares if SNDX falls ~39% to $13, which would imply a post-assignment cost basis of $10.20 per share (subtracting the $2.80 premium). The write-up stresses that upside for the put seller is limited to the premium and recommends combining volatility, the stock's trading history, and fundamental analysis to assess risk/reward.

Analysis

Market structure: Options sellers (income strategies) and volatility markets win short-term if premium (10.4% annualized) is collected and SNDX holds above the $13 strike (39% below today’s $21.36). Buyers of downside protection and retail holders lose if a binary negative biotech event forces a >39% drop. With trailing vol at 68%, liquidity providers and brokers capture spreads; implied vol shocks in SNDX will spill into small-cap biotech ETFs (XBI, IBB) and raise hedging demand that can bid rates on corporates if risk-off widens credit spreads.

Risk assessment: Tail risks are binary trial/FDA failures or acute cash/dilution events that could wipe 40–70% of value (assignment leaves put-seller with a $10.20 cost basis, ~52% below current). Immediate (days) risk: IV repricing around news; short-term (weeks–months): readouts or financing needs; long-term (years): structural dilution or repositioning via partnerships. Hidden dependencies include cash runway, milestone payments, and investor forced-selling from concentrated option assignments; catalysts include any trial readouts, partnership announcements, or a financing within 60–180 days.

Trade implications: Direct: if willing to own SNDX at deep discount, sell the Jan‑2028 $13 put sized to 0.5–2% of NAV and collect premium, but hedge with a $8 long put to form a 13/8 put spread to cap downside; close if SNDX > $30 or IV falls <45%. If long shares, buy a near-term 9–15 month $15 protective put. Rotate portfolio 2–4% from small-cap biotech (XBI) into large-cap healthcare (JNJ/PFE/XLV) to reduce idiosyncratic tail risk.

Contrarian angles: The consensus underweights the cost of binary downside — 10.4% annual yield understates expected loss given 68% vol and potential >50% drawdowns; selling naked puts is likely underpriced for true tail risk. Historical parallels: small-cap biotechs often gap down 40–80% on negative readouts and stay depressed for 6–18 months, so prefer capped-risk structures or wait for price < $13 (or IV <40%) before outright long exposure. Unintended consequence: assignment can force capital strain and create liquidation cascades during sector-wide volatility.

Key Decisions for Investors

• Establish a sell-put spread: sell Jan‑2028 SNDX $13 put and buy Jan‑2028 $8 put (size 0.5–2% NAV) to capture ~10%+ annualized yield while capping downside; close if SNDX > $30 or implied vol drops below 45% within 3 months.
• If you already own SNDX shares, buy a 9–15 month $15 protective put (limit cost to <8% of position) to guard against binary trial/FDA risk expected in the next 60–180 days.
• Avoid naked long exposure >1% NAV to SNDX until either (a) shares trade below $13 (preferred entry) or (b) implied vol falls under 40% and there is at least one positive catalyst; otherwise prefer capped-risk structures.
• Rotate 2–4% of portfolio from small-cap biotech exposure (XBI) into large-cap defensive healthcare (JNJ, PFE or XLV) over the next 2–4 weeks to reduce idiosyncratic binary risk ahead of expected sector readouts.
• Monitor specific catalysts: require clear funding runway or a positive trial milestone within 60–180 days before increasing exposure; if SNDX announces a financing that dilutes >10% or a negative readout, reduce exposure to zero and cover short-dated sold puts immediately.